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RESUMEN
El síndrome hemolítico urémico (SHU) es una entidad clínica
definida por la tríada anemia hemolítica no inmune, trombo-
citopenia e insuficiencia renal aguda, en la que las lesiones sub-
yacentes están mediadas por un proceso de microangiopatía
trombótica (MAT) sistémica. El SHU atípico (SHUa) es un subti-
po de SHU en el que los fenómenos de MAT son consecuencia
de la pérdida de regulación de la vía alternativa del comple-
mento sobre las superficies celulares de causa genética. El SHUa
es una enfermedad ultra-rara que, pese al tratamiento están-
dar con terapia plasmática, frecuentemente evoluciona a la in-
suficiencia renal crónica terminal, con elevada mortalidad. En
los últimos años, se ha establecido el papel clave que desem-
peña el sistema del complemento en la inducción de daño en-
dotelial en los pacientes con SHUa, mediante la caracterización
de múltiples mutaciones y polimorfismos en los genes que co-
difican determinados factores del complemento. Eculizumab
es un anticuerpo monoclonal que inhibe la fracción terminal
del complemento bloqueando la formación del complejo de
ataque de membrana. En estudios prospectivos en pacientes
con SHUa su administración ha demostrado la interrupción rá-
pida y sostenida del proceso de MAT, con mejorías significati-
vas de la función renal a largo plazo y con una reducción im-
portante de la necesidad de diálisis o terapia plasmática. En el
presente documento se revisan y actualizan los diversos aspec-
tos de interés de esta enfermedad, con especial atención a
cómo los recientes avances diagnósticos y terapéuticos pueden
modificar el tratamiento de los pacientes con SHUa.
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INTRODUCTION
Haemolytic uraemic syndrome (HUS) is a clinical entity
defined by the triad of non-immune haemolytic
ABSTRACT
Haemolytic uraemic syndrome (HUS) is a clinical entity
defined as the triad of nonimmune haemolytic anaemia,
thrombocytopenia, and acute renal failure, in which the
underlying lesions are mediated by systemic thrombotic
microangiopathy (TMA). Atypical HUS (aHUS) is a sub-type
of HUS in which the TMA phenomena are the consequence
of decreased regulation of the alternative complement
pathway on cell surfaces due to a genetic cause. aHUS is an
extremely rare disease that, despite the administration of
standard treatment with plasma therapy, often progresses
to terminal chronic renal failure with a high associated rate
of mortality. In recent years, research has established the
key role that the complement system plays in the induction
of endothelial damage in patients with aHUS, through the
characterisation of multiple mutations and polymorphisms
in the genes that code for certain complement factors.
Eculizumab is a monoclonal antibody that inhibits the
terminal fraction of the complement protein, blocking the
formation of a cell membrane attack complex. In
prospective studies in patients with aHUS, administering
eculizumab produces a rapid and sustained interruption in
the TMA process, with significant improvements in long-
term renal function and an important decrease in the need
for dialysis or plasma therapy. In this document, we review
and bring up to date the important aspects of this disease,
with special emphasis on how recent advancements in
diagnostic and therapeutic processes can modify the
treatment of patients with aHUS.
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microangiopathic anaemia, thrombocytopenia, and acute
renal failure.1 Histological damage from HUS is
characterised by the appearance of systemic thrombotic
microangiopathy (TMA), which primarily affects the renal
blood vessels, producing thickening of the vessel wall,
thrombosis, and obstruction of the vascular lumen. The
majority of cases of HUS are caused by an enteric infection
by shiga toxin-producing Escherichia coli (STEC) or other
micro-organisms that produce verotoxin (VTEC), giving
way to the so-called typical HUS or STEC (VTEC)-HUS. In
a similar manner, TMA lesions and HUS can be secondary to
other underlying diseases, drugs, certain types of organ
transplants, or pregnancy. Rarely, HUS is produced as the
consequence of deregulation of the alternative pathway for
the complement system due to genetic abnormalities, which
leads to endothelial damage and convey systemic TMA.2
This type of HUS is known as atypical HUS (aHUS),
constituting a severe disease associated with a poor
prognosis and elevated mortality rates. The prognosis for
aHUS is sombre despite recommendations for intensive
treatment regimens with plasma therapy (PT) and life
support measures. More than 50% of patients with aHUS die
from this disease, require dialysis, or develop permanent
kidney damage during the year following diagnosis.3
Recent advances in the characterisation of the genetic
component of aHUS (including the identification of multiple
mutations and polymorphisms in the genes that code for
certain complement proteins) have led to the conclusion that
the endothelial damage produced by the complement system
is the critical factor in the pathophysiology of this disease, and
the hypothesis that inhibition of the complement system is a
viable treatment option in these patients. In 2011, the
governing regulatory agencies of the United States and Europe
approved the indication for eculizumab (Soliris®; Alexion
Pharmaceuticals, Connecticut, USA),4 a humanised
monoclonal antibody that inhibits the activation of C5 and
blocks the generation of the proinflammatory anaphylotoxin
C5a and the lytic pathway of the complement system (which
produces cell lysis), for the treatment of aHUS.5 In prospective
studies of patients with aHUS, eculizumab has been shown to
effectively interrupt the process of TMA and its consequences,
associated with significant long-term improvements in
haematological parameters and renal function.6-9
With the objective of elaborating updated diagnostic and
treatment protocols for aHUS, a consensus conference was
held on February 2 and 3 of 2012 in Barcelona, which
brought together clinical and research experts in the field of
TMA. Using the platform of the available scientific evidence
and clinical experience, this conference discussed various
aspects of interest of the disease, such as the aetiological
classification of TMA, the pathophysiology of aHUS, and
differential diagnosis, and recommendations were made for
treating patients with aHUS. This article summarises the
primary conclusions derived from this meeting.
AETIOLOGICAL CLASSIFICATION OF THROMBOTIC
MICROANGIOPATHY
The term TMA defines a histological lesion found in the
arterioles and capillaries that is characterised by thickening
and inflammation of the vascular wall, detachment of endothelial
cells, subendothelial widening due to the accumulation of
proteins and cellular debris, and platelet thrombi that occlude the
vascular lumen (Figure 1).1 Two different clinical entities are
characterised by primary TMA lesions, which have different
causes and histopathological foundations: thrombocytopenic
thrombotic purpura (TTP) and HUS.
Intravascular thrombosis in TTP is the consequence of a severe
deficiency of metalloprotease activity of the ADAMTS13 (A
Disintegrin And Metalloproteinase with a ThromboSpondin type
1 motif, member 13), a plasma enzyme responsible for
fragmenting the ultra-long multimeres of the von Willebrand
factor.10 This deficiency can be caused by genetic abnormalities
or can be acquired through circulating IgG antibodies that block
ADAMTS13 (especially in patients on treatment with anti-
platelet medications).11
Approximately 90% of cases of HUS are caused by an enteric
infection by STEC from contaminated foods (typical
HUS/STEC[VTEC]-HUS).2 The shiga toxin exerts a direct
damaging effect on the vascular endothelium, triggering
multiple cellular and vascular phenomena that lead to the
Figure 1. Renal histopathological lesions from haemolytic
uraemic syndrome.
A. Ischaemic and retracted glomeruli; B. Mesangiolysis; C.
Thrombi in the glomerular capillaries (arrow); D. Artery
occluded by platelet thrombi.
Photographs courtesy of Dr R. Ortega (Histopathology
department of the Hospital Universitario Reina Sofía de
Córdoba).
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development of TMA.2 The disease appears clinically in the
form of abdominal pain and diarrhoea, with acute renal failure
appearing after 4-10 days. The prognosis tends to be good:
mortality is <5% and a complete clinical recovery is achieved
in 80% of patients.12,13
In contrast, aHUS is a disease in which the TMA phenomena
are the consequence of a deregulation of the alternative
complement pathway on cell surfaces. This alteration can be
produced by mutations or polymorphisms that decrease the
activity of complement regulating proteins, or that increase the
function of activator proteins. In both cases, activation of the
complement system (induced by a range of triggering factors) is
not appropriately controlled, provoking endothelial damage and
thrombosis. Of the more than 1000 patients with aHUS
published in the medical literature, mutations have been
detected in one or more complement proteins in 50%,14-21
although we cannot rule out that in the other cases there may
have also been a genetic or environmental component involved
that could have affected the abnormal complement system
activity. In fact, it is notable that auto-antibodies against
complement factor H (FH) are found in 5%-10% of patients
with aHUS.22 In contrast to STEC-HUS, which tends to occur as
a single event, aHUS is a chronic condition due to the genetic
origins of the disease, and involves a poor prognosis. After the
first episode of aHUS, mortality is 10%-15%, and 50% of
patients will never recover renal function.3,14,15
In addition to infection by STEC or genetic deregulation of
the complement system, there are many other clinical entities
and triggering factors that can be associated with the
development of HUS or TTP (secondary TMA). In children,
some cases are associated with methylmalonic aciduria23 or,
more frequently (5% of cases of HUS in children), with
invasive infections by Streptococcus pneumoniae strains that
produce the enzyme neuraminidase, which exposes the
cryptoantigen T in the cell surface, thus producing TMA,24 or
by H1N1 virus infection.25 In adults, cases of TMA have been
described in association with human immunodeficiency virus
(HIV) infection, certain types of cancer, drugs (chemotherapy
agents, calcineurin inhibitors [cyclosporine and tacrolimus],
mTOR [mammalian target of rapamycin; sirolimus,
everolimus] inhibitors, vascular endothelial growth factor
inhibitors, anti-platelet agents, and oral contraceptives,
among others), malignant arterial hypertension, bone marrow
and solid organ transplantation, pregnancy, and systemic
diseases (systemic lupus erythematosus, scleroderma, and
antiphospholipid syndrome).26
Table 1 displays the proposed aetiological classification of
TMA. In certain patients more than one aetiological factor
responsible for the TMA lesion may coexist, producing a
variety of clinical presentations. Recently, it has been shown
that as many as 25% of patients with STEC-HUS, and 86%
of patients with HUS secondary to pregnancy, may have
mutations in complement system gene sequences,27,28 which
could signify that the underlying cause of these cases is in
reality aHUS. In this context, Figure 2 represents the
potential overlap that could occur between these two clinical
entities. The primary motivation for discussion in this article
is an update of aHUS mediated by altered complement
regulation, and the following sections will refer exclusively
to this entity.
ATYPICAL HAEMOLYTIC URAEMIC SYNDROME:
CLINICAL ENTITY
Epidemiology
aHUS is considered to be an extremely rare disease. Very
few sources of data are available regarding the incidence and
prevalence of this condition, severely limiting our
understanding of its true epidemiology. In the United States,
aHUS is estimated to have an annual incidence rate of ~1-2
cases/million inhabitants.29 In Europe, a recent international,
multi-centre study reported an incidence of 0.11
cases/million inhabitants between the ages of 0 and 18 years.
As regards prevalence, the EMA (European Medicines
Agency) estimates approximately 3.3 patients/million
inhabitants/year in individuals younger than 18 years of age,
with lower rates in adults.
aHUS primarily affects children and young adults, although
it can appear at any stage of life.14,15 The start of the disease is
more common before the individual has reached 18 years of
age (60% vs. 40%), and the sex distribution is similar (with a
slight predominance in females when the disease appears
later in life).14,16
Clinical manifestations
The initial onset of this disease can be abrupt, although it may
occur progressively in approximately 20% of patients (a matter
of weeks or months), with sub-clinical anaemia, fluctuating
thrombocytopenia, and conserved renal function.14 Symptoms
are characterised by the triad of non-immune microangiopathic
haemolytic anaemia, thrombocytopenia, and acute renal failure.1
High levels of lactate dehydrogenase (LDH), undetectable
haptoglobin levels, and schistocytes confirms the presence of
intravascular haemolysis.3 Patients also develop haematuria,
proteinuria, and/or acute renal failure (with or without
oligoanuria). Arterial hypertension is a common finding,
whether due to volume overload or vascular damage.1
Although aHUS predominantly affects the renal vessels, the
diffuse character of TMA phenomena leads to involvement
of the microvasculature of other organ systems (the brain,
heart, intestines, pancreas, and lungs),1 which explains the
common appearance of extra-renal symptoms.14,15 The most
frequent of these symptoms are neurological (48%),30 which
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can include irritability, somnolence, confusion, convulsions,
encephalopathy, cerebrovascular accidents, hemiparesia,
hemiplexia, and coma.1,15,30,31 Myocardial infarction has also
been described in as many as 3% of patients with aHUS, and
can cause sudden death.15,32 Cardiomyopathy, heart failure,
and peripheral ischaemic heart disease have also been
described,22,30,33,34 in addition to diarrhoea (30%) and other
gastrointestinal symptoms (colitis, nausea and vomiting, and
abdominal pain).15,22,31,35 The variability in symptoms
presented is an impediment to performing a differential
diagnosis in comparison with other sources of TMA.
Pathophysiology
The complement system, which is composed of numerous
proteins in plasma and in the cellular membranes, is essential
in the defence against infection, the processing of immune
complexes, the antibody responses, and the elimination of
cell remnants from apoptosis. The activation of the
complement system through any of the known pathways
(classical/lectin and alternative pathways) leads to the
formation of multi-protein complexes with C3-convertase
activity that cleaves C3, generating C3b (Figure 3). This
molecule can bind covalently to the cell surfaces responsible
for complement activation, facilitating phagocytosis by
polymorphonuclear leukocytes and macrophages, and
initiating the cell membrane attack complex that induces
cellular lysis. In addition, C3b exponentially amplifies the
activation of the complement system, promoting the
formation of more C3-convertase.36 In order to avoid
complete consumption by the activation of the complement
system as well as damage to untargeted tissues (C3b binds
indiscriminately to both pathogenic cells and native somatic
cells), a number regulatory proteins such as complement
factor H (FH), membrane cofactor protein (MCP), and
complement factor 1 (F1) act to dissociate the C3-convertase
Table 1. Aetiological classification of thrombotic
microangiopathies
TTP associated with genetic or immune abnormalities of
ADAMTS13 (activity <_ 5%)   
- Genetic
- Antibodies (associated with ticlopidine and 
clopidogrel)
HUS associated with infections (STEC and STEC-like)
- HUS from STEC infection (VTEC) strain O157:H7 and
other non-O157:H7 strains, Shigella disenteriae type I
- HUS associated with Streptococcus pneumoniae
infection (neuraminidase)
Atypical HUS associated with genetic abnormalities or
immune system alterations of the complement system
- Mutations in CFH, MCP, CFI, THBD, CFB and C3
- Anti-CFH antibodies
Secondary TMA
- Pregnancy
HELLP syndrome
Postpartum
- Diseases
- Systemic
SLE
Anti-phospholipid syndrome
Scleroderma
- Other
HIV infection
Glomerulopathies
Malignant arterial hypertension
H1N1 infection (influenza A)
Cancer
Methylmalonic aciduria with homocysteinuria
- Treatments
- Quinine
- Mitomycin
- Gemcitabine 
- Cisplatin 
- Ionising radiation
- Interferon 
- VEGF and tyrosine kinase (sunitinib, imtinib, 
and dasatinib)
- Ticlopidine and clopidogrel
- Calcineurin inhibitors (cyclosporine, tacrolimus)
- Sirolimus
- Valaciclovir
- Oral contraceptives
- Solid organ and bone marrow transplants
ADAMTS13: a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13; CFB: complement
factor B gene; CFH: complement factor H gene; CFI:
complement factor I gene; HELLP: haemolysis, elevated liver
enzymes, low platelet count; SLE: systemic lupus
erythematosus; TMA: thrombotic microangiopathy; MCP:
membrane cofactor protein; STEC: shiga toxin producing
Escherichia coli; THBD: thrombomodulin gene; VEGF: vascular
endothelial growth factors; HIV: human immunodeficiency
virus; VTEC: verotoxin producing Escherichia coli.
Figure 2. Representation of the clinical overlap of the
different types of haemolytic uraemic syndrome.
HUS: haemolytic uraemic syndrome; STEC: shiga toxin
producing Escherichia coli. 
Haemolytic uremic syndrome
Atypical HUS
Secondary
HUS
STEC- and
STEC-like
HUS
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and induce the degradation of C3b. As a consequence, under
normal conditions, C3b is maintained at low levels, and when
the complement system is activated, its deposition is limited
to those structures responsible for the activation.
Multiple studies have reported that 40%-60% of patients
with aHUS carry of mutations in the complement system
genes (complement factor H gene [CFH], membrane
cofactor protein gene [MCP], complement factor B gene
[CFB], and C3 gene [C3]),37-46 which are related to
deregulation of the alternative pathway (Table 2). FH acts in
the plasma controlling homeostasis of the complement
system, as well as avoiding damage to self cell surfaces.
Mutations in the FH gene associated with aHUS cluster at
the C-terminal region, which results in a decreased FH-
mediated protection of cell surfaces against accidental
damage produced through activation of the complement
system, but does not affect complement regulation in the
plasma.47 One conclusion from the functional analyses
performed with these FH mutants is that aHUS is the
consequence of damage caused by the complement system
due to the dysregulation of the complement activation on
self cell surfaces. Functional analyses of mutations
associated with aHUS found in other complement genes,
Figure 3. Complement dysregulation in atypical haemolytic uraemic syndrome.
Activation of the complement system by any of its three mechanisms (recognition of foreign antigens, alternative pathway,
antibodies, classical pathway; or mannan polysaccharides (lectin pathway) leads to the deposition of large quantities of C3b on the
activator cell membrane, which produces opsonisation and C5 activation (lytic pathway), which in turn produces the membrane
attack complex and cell lysis. Activation of the complement system produces inflammation and recruitment of leukocytes. C3b
production is the fundamental process in complement activation, and is also the best regulated. For the creation of C3b, unstable
enzymatic complexes known as C3-convertases are needed, which catalyse the rupture of C3 to create C3b. C3b, in turn, is capable
of forming more C3-convertase through the alternative pathway (C3bBb), thus amplifying the initial activation. The production of
C3b is regulated at two levels: dissociation of C3-convertase, and proteolytic inactivation of C3b and C4b. Several regulatory proteins
in the plasma and cell membrane carry out this regulatory activity. Among these, factor H, MCP, and factor I play key roles in the
dissociation of alternative pathway C3-convertase (C3bBb) and the proteolytic degradation of C3b. Mutations in these genes
observed in patients with aHUS interfere with this regulatory function of the activation of the alternative pathway.
MAC: membrane attack complex; MCP: membrane cofactor protein gene; aHUS: atypical haemolytic uraemic syndrome.
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such as MCP, CFI, CFB, and C3, have confirmed the
hypotheses anticipated in the studies with FH mutants,
demonstrating, in addition, that dysregulation of complement
on cell surfaces in aHUS may be due to decreased activity of
the regulatory proteins or to an abnormally high activity of
the C3-convertase. In this context, whereas mutations in FH,
MCP, FI, and thrombomodulin (THBD) incapacitate these
proteins from being able to carry out their regulatory
function, mutations in complement factor B (FB) or in C3
result in a more active C3-convertase.
Anti-FH auto-antibodies directed towards the C-terminal
region are found in 5%-10% of all patients with aHUS, with
similar consequences to those produced by FH mutations.48,49
The role of these mutations in the pathogenesis of aHUS is
not completely understood, but it appears to be associated
with both the onset and the recurrences of disease. Antibody
titres decrease with time, and should be measured at the first
indication of aHUS.
Penetrance of aHUS in carriers of mutations in the
complement genes is approximately 50%. It is common that
in families with complement mutations only some carriers
develop aHUS, with variable clinical presentations. There is
also a wide range of clinical heterogeneity between unrelated
patients with the same mutation. This suggests that
additional genetic and environmental factors must exist that
modulate the development and progression of this disease.
The search for aditional mutations to genes in complement
genes in patients with aHUS along with case-control
association studies that using genetic polymorphisms in
candidate genes or genetic markers distributed throughout
the whole human genome have demonstrated that certain
variants (polymorphisms) in the genes CFH and MCP
modulate the presence and severity of this disease (Table
2).41,50,51 These observations, along with the fact that as many
as 10% of patients with aHUS have mutations in more than
one complement gene, indicates that the coincidence of
different genetic risk factors is a determining factor in the
development of aHUS (multiple hits theory).51
In addition to these genetic abnormalities, the onset of
aHUS involves the participation of triggering environmental
factors. The aforementioned mutations predispose the
patient to disease, hampering adequate regulation of the
complement system on cell surfaces in a situation that
affects the microvasculature system. Infectious diseases can
trigger aHUS in 50%-80% of patients,14,15,33 especially
diseases of the upper respiratory tract (H1N1 virus).
Diarrhoea from gastroenteritis may precede aHUS in as
many as 30% of cases (including STEC diarrhoea14,15,22). In
women, pregnancy can also be a triggering factor for
aHUS.15,28
Prognosis
Table 3 displays the clinical evolution of patients with
aHUS based on the type of mutation involved. In general,
patients with FH and C3 mutations have a worse prognosis
during the episode of aHUS and following months, with
rates of mortality and terminal chronic renal failure (TCRF)
or recurrence of 50%-70% and 50%, respectively. On the
other hand, only 0.6% of patients with MCP mutations dies
or develops TCRF, although the risk of recurrence is greater.
Three out of four patients with FH, C3, or FB mutations die
or develop TCRF.1
Table 2. Risk factors for atypical haemolytic uraemic
syndromea
Mutations
- Loss of function
CFH (~13%)
MCP (~11%)
CFI (~10%)
THBD (~4%)
- Gain of function
C3 (~4%)
CFB (~3%)
Polymorphisms
- Increased risk
CFH: c.-332C>T; c.2016A>G (p.Gln672Gln); c.2808G>T
(p.Glu936Asp)
MCP: c.-652A>G; c.-366A>G; c.989-78G>A; a897T>C
- Protection conferred
CFH: c.184G>A (p.Val62Ile)
Auto-antibodies
- Anti-FH (~5%)
Environmental factors
- Infections
- Immunosuppressants
- Oral contraceptives
- Anti-cancer drugs
Anti-FH: anti-complement factor H antibody; CFB: complement
factor B gene; CFH: complement factor H gene; CFI:
complement factor I gene; MCP: membrane cofactor protein
gene; aHUS: atypical haemolytic uraemic syndrome; THBD:
thrombomodulin gene.
a Multiple hits theory. aHUS is a complex disease that normally
involves the combination of multiple genetic and environmental
risk factors. It is not uncommon that patients will have more
than one mutation in the genes coding for complement factors,
or a combination of mutations with risk-associated
polymorphisms. The concurrence of one mutation with others,
with risk-associated polymorphisms, with auto-antibodies, or
with triggering environmental factors, explains the incomplete
penetrance of aHUS, as well as the differences in its presentation
and progression, in patients with mutations to complement
genes.
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recommended to be performed in patients with a suspected
diagnosis of aHUS.2 Due to the rapid and severe progression
of TMA, the diagnostic process must first involve an
immediate phase (first 24 hours) that involves identifying the
syndrome responsible and instating initial support measures,
followed by a second phase of aetiological diagnosis.
In patients with TMA, laboratory results indicate the
presence of thrombocytopenia (platelets <150 000mm3 or
decrease of >25% since initial level3) and microangiopathic
haemolysis (haemoglobin <10mg/dl with a negative direct
Coombs test result [although some patients with HUS related
to pneumococcal infection may have a positive direct
Coombs test result],24 elevated LDH, decreased haptoglobin
levels, reticulocytosis, and schystocytes3,56). Although it is
possible to detect schistocytes in the majority of patients
with kidney disease, preeclampsia, and mechanical valves, a
number of schistocytes >1% is diagnostic of TMA when in
the absence of another known cause.58
Elevated serum creatinine levels, low glomerular filtration
rates (GFR), proteinuria, or haematuria would be indicative
of renal dysfunction.3,14,54 In paediatric patients, a renal
biopsy is not needed for diagnosis. A renal biopsy is usually
indicated in adult patients in the case of acute renal failure in
order to establish the aetiology of the disease, rule out other
processes, and evaluate prognosis, although the indications
for biopsy should be individually evaluated in patients
suspected of TMA due to a risk of bleeding.
A complete clinical history is imperative, including family
history, triggering factors, and an exhaustive physical
examination. Contrary to medical opinion several years ago,
it is currently held that the signs and symptoms for different
types of TMA are not specific to each individual form, and
so a differential diagnosis is not feasible.1 Traditionally, the
Recurrence of atypical haemolytic uraemic
syndrome after kidney transplantation
The results of kidney transplants (KT) in patients with TCRF
caused by aHUS have been limited historically by the high
percentage of post-transplant recurrence of disease (~50%;
graft loss rate: 80%-90%52,53), although results vary based on
the type of mutation present. FH mutations are associated
with a greater risk of recurrence or graft loss following KT
(75%-90%), and high levels of risk are also associated with
C3 and FI mutations (40%-80%; Table 3).15,35,40,54 Until now,
very few transplants have been attempted in patients with FB
mutations, but all cases that have been reported to date have
involved recurrence of aHUS and graft loss.41,55 In general, the
plasma complement factors involved in aHUS are primarily
synthesised by the liver, and so patients with mutations to
complement genes that code for these factors continue to be
susceptible to aHUS after KT, since the dysfunctional factors
continue to be produced. On the other hand, MCP is a trans-
membrane protein primarily produced by the kidney, and so a
KT may correct the deficit by producing unaltered MCP in
the new kidney. More than 80% of patients with MCP
mutations do not develop recurrent aHUS after KT, with a
similar long-term survival rate to that of patients who receive
transplants for other reasons.33,52,53 The risk of post-transplant
recurrence in patients with THBD56 or anti-FH antibody
mutations is not well understood, although in the case of FH
antibodies, it appears that recurrence is related to persistently
high antibody levels.22,57
DIAGNOSIS OF ATYPICAL HAEMOLYTIC URAEMIC
SYNDROME
Figure 4 and Table 4 display the algorithm for the
differential diagnosis of TMA and the biological tests
Table 3. Clinical characteristics of patients with atypical haemolytic uraemic syndrome based on complement
abnormality
Gen Risk of death or TCRF in the Risk of recurrence Risk of death or TCRF Risk of recurrence after 
first episode or one  after 3-5 years kidney transplant
year after
CFH 50-70% 50% 75% 75-90%
CFI 50% 10-30% 50-60% 45-80%
MCP 0-6% 70-90% 6-38%a < 20%
C3 60% 50% 75% 40-70%
CFB 50% 3/3 not with TCRF 75% 100%
THBD 50% 30% 54%a 1 patient
Anti-FH 30-4 0% 40-60% 35-60%a Greater with elevated 
antibody levels
Anti-FH: anti-complement factor H antibodies; CFB: complement factor B gene; CFH: complement factor H gene; CFI: complement
factor I gene; TCRF: terminal chronic renal failure; MCP: membrane cofactor protein gene; THBD: thrombomodulin gene.
a Data for TCRF.
Adapted from Loirat.1
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Figure 4. Algorithm for the differential diagnosis of primary thrombotic microangiopathy.
ADAMTS13: a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; LDH: lactate dehydrogenase;
TMA: thrombotic microangiopathy; TTP: thrombotic thrombocytopenic purpura; HUS: haemolytic uraemic syndrome; aHUS: atypical
haemolytic uraemic syndrome; STEC: shiga toxin producing Escherichia coli.
a Negative direct Coombs test; b The shiga toxin test/STEC is indicated when the patient has a history of digestive system
involvement or gastrointestinal symptoms; c Rarely, in some patients with aHUS, STEC infection can trigger the underlying disease.
Table 4. Tests recommended for the diagnosis of atypical haemolytic uraemic syndrome.
STEC infection Faecal sample (diarrhoea) or rectal swab: STEC cultures (MacConkey for E. coli O157:H7); PCR for 
Stx genes O157:H7 and other serotypes, and other virulent characteristics; ELISA and/or Vero 
cell tissue culture assay for Stx serum: anti-LPS antibodies for prevalent serotypes 
Pneumococcus infection Bacterial culture (generally) of sterile body fluids: DAT (Coombs test), viral test (respiratory), 
chest x-ray (pleural effusion as a characteristic of most cases), cytochemistry, and LCR culture 
in cases secondary to meningitis caused by a pneumococcus.
Altered regulation of the C3, C4 (plasma/serum), AH50
complement system FH, FI, FB (plasma/serum)
Anti-FH auto-antibodies
Expression of superficial MCP on leukocytes (poly- or mononuclear leukocytes using FACS test)
Mutation analysis for FH, FI, MCP, C3, FB ± THBD
ADAMTS13 deficiency Plasma activity of ADAMTS13 or dose (ELISA) ± inhibitor
(acquired or hereditary)
Cobalamine metabolism: Amino acid chromatography in plasma/urine samples (hyperhomocysteinemia, hypomethioninemia, 
methylmalonic aciduria homocysteinuria); organic acid chromatography in urine samples (methylmalonic aciduria)
Mutation analysis for the gene MMACHC
HIV Serology, viral load (PCR)
H1N1 virus Culture and PCR
Pregnancy, HELLP syndrome Pregnancy test, liver enzyme levels. Analysis same as lines 3 and 4
Other Anti-nuclear antibodies, lupus anticoagulants, and anti-phospholipid antibodies
ADAMTS13: a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; DAT: direct antiglobulin test;
ELISA: enzyme-linked immunoabsorption assay; FACS: fluorescence activated cell sorting; FB: complement factor B; FH: complement
factor H; FI: complement factor I; HELLP: haemolysis, elevated liver enzymes, low platelet count; CSF: cerebrospinal fluid; 
MCP: membrane cofactor protein; PCR: polymerase chain reaction; STEC: shiga toxin producing Escherichia coli; 
THBD: thrombomodulin; HIV: human immunodeficiency virus.
Adapted from Loirat.2
Thrombocytopenia 
<150 000 or >25% deterioration
Evaluate ADAMTS13 activity and shiga toxin/STEC testb
<_5% ADAMTS13 activity >5% ADAMTS13 activity Shiga toxin/STEC positive
TTP aHUS Secondary TMA STEC-HUSc
More than one of the following:
Neurological symptoms: 
Confusion and/or convulsions
Renal involvement:
elevated creatinine levels and/or
decreased glomerular filtration
rate and/or urine abnormalities
Gastrointestinal
involvement: 
Diarrhoea and/or
nausea/vomiting, abdominal
pain, gastroenteritis
Microangiopathic haemolysis 
Elevated LDH and/or decreased
haptoglobin, and/or schistocytes,
and/or decreased haemoglobina
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distinction between HUS and TTP was based on clinical
criteria, considering HUS to be an entity with predominately
renal involvement, and TTP as primarily affecting the
neurological system. However, it has been shown that 50% of
patients with TTP have renal dysfunction, and 50% of
patients with aHUS have neurological alterations.30,59 It is also
impossible to use clinical symptoms to differentiate between
STEC-HUS and aHUS, since as many as 30% of patients
with aHUS first experience symptoms of gastroenteritis15 or
diarrhoea,35 characteristic symptoms of STEC-HUS.
Detection of shiga toxin or positive STEC cultures in
patients with TMA is diagnostic of STEC-HUS,27 whereas
the diagnosis of TTP requires a direct demonstration that
plasma activity of ADAMTS13 is ≤5%.60 In all other cases,
the diagnosis should be orientated towards aHUS,60 requiring
additional tests to rule out secondary forms of TMA.
TREATMENT FOR ATYPICAL HAEMOLYTIC URAEMIC
SYNDROME
Plasma therapy
The two modalities of plasma therapy are plasma infusion
(PI) and plasma exchange (PE). PI involves viro-inactive,
non-native, fresh frozen plasma (FFP) with functional
complement regulators.61 In PE, the patient receives FFP to
replace the native plasma with aHUS, which implies the
administration of not only elevated levels of functional
complement regulatory proteins, but also the elimination of
dysfunctional endogenic soluble complement inhibitors, with
a lower risk of volume overload. In addition, PE purifies the
blood of anti-FH antibodies and the possible presence of
inflammatory/thrombogenic factors that participate in
producing endothelial damage and platelet hyper-aggregation.
Traditionally, the treatment of choice recommended for
episodes of aHUS consisted of early and intensive PE at high
volumes and a variable frequency based on disease activity,
whereas PI tends to be ineffective, except for in the few
patients with complete deficit of FH.62 In general, PT is not
considered to be effective in patients with MCP mutations,
since this is a non-circulating protein anchored in the cell
membrane, and virtually all of these patients go into
remission after the episode of aHUS, regardless of the use of
PT.15
Although information from prospective clinical trials is not
available, PT has been empirically the treatment of choice
for aHUS for several years, after observing more than three
decades ago that this treatment decreases mortality rates in
patients with HUS-TTP. Table 5 presents the results of the
largest international registry of PT in patients with aHUS
(International Registry of Recurrent and Familial HUS/TTP),
which included 273 patients diagnosed between 1996 and
2007.15 In this registry, the rates of complete haematological
and renal recovery in patients treated with PT were generally
lower than 50% (with the exception of patients with THBD
and MCP mutations), and these rates were especially low in
patients with FH and FI mutations (5% and 12.5%).15
Mortality and progression of TCRF are globally high,
occurring in 3 out of 4 patients with FI mutations. Certain
observations indicate that early and intensive PE is essential
for salvaging patients from aHUS, and maintenance of this
type of treatment can prevent disease recurrence and
TCRF,14,61 but we still have yet to establish the most effective
treatment regimen, nor do we fully understand the long-term
impacts of this type of therapy on renal function.
In patients with anti-FH antibodies, it has been shown that
concomitant immunosuppressant treatment along with PT
can improve results.22,63,64 In these cases, an elevated antibody
titre is correlated with a greater risk of recurrence and renal
sequelae.22
The appearance of anaphylactic reactions to FFP,
hypervolemia, hypertension, heart failure, and
hyperproteinaemia are potential complications of PI. The
primary complications that arise due to PE are venous access
obstruction (6%), hypotension (5%), and allergy (4%),65 and
these are most common in paediatric patients.65
Eculizumab
Eculizumab is an IgG
2/4κ humanised monoclonal antibody
that binds to complement C5 proteins with great affinity,
blocking its excision into C5a and C5b and impeding the
production of the C5b-9 terminal complement complex
(membrane attack complex) (Figure 3).5 In aHUS,
deregulation of the alternative complement pathway leads to
uncontrolled activation of this process, provoking damage to
endogenous structures through the formation of membrane
attack complexes. In this sense, blocking the terminal
complement complex with eculizumab quickly and
sustainably diminishes this activity, and in many cases of
patients with aHUS that receive this treatment, a good
clinical response to the drug has been reported (Table
6).31,35,54,66-84
The efficacy and safety of eculizumab as a treatment for
aHUS was evaluated recently in two phase II prospective,
multi-centre, controlled, open clinical studies of 26 weeks
duration, carried out in patients ≥12 years of age and with
primary or recurrent (post-KT) disease.85,86 One included 17
patients resistant to PT (≥4 sessions/week) (Study C08-002)85
and one included 20 patients on chronic plasma treatment
(≥8 weeks) (study C08-003).86 The most common mutations
in this sample were related to FH (15 patients) and FI.8 Three
patients had MCP mutations, three had C3, and one had FB.
We found anti-FH antibodies in 4 patients and no genetic
abnormalities were observed in 10 patients. In both studies,
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Table 5. Prognosis of patients with atypical haemolytic uraemic syndrome treated with plasma infusion or plasma
exchange
Remission Death or terminal renal failure
CFH 63% 37%
(complete: 5%; partial: 58%)
CFI 25% 75%
(complete: 12,5%; partial: 12,5%)
C3 57% 43%
(complete: 43%; partial: 14%)
THBD 88% 13%
(complete: 62%; partial: 25%)
Anti-FH antibodies 75% na
(complete: 25%; partial: 50%)
MCP 97% of treated patients na
(complete: 90%; partial: 7%) 
and 100% of non-treated patients
Complete remission: normalisation of haematological parameters and renal function. Partial remission: normalisation of
haematological parameters and sequelae of kidney issues.
Anti-FH: anti-complement factor H antibodies; CFH: complement factor H gene; CFI: complement factor I gene; MCP: membrane
cofactor protein gene; na: not available; THBD: thrombomodulin gene.
Adapted from Noris.15
the response to eculizumab was similar between patients with
mutations and/or ant-FH antibodies and those with no genetic
abnormalities. The response was also similar regardless of the
type of mutation identified. After 6 months of treatment with
eculizumab, rates of haematological normalisation (≥2
consecutive normal measurements of platelets and LDH)
reached 76% in resistant cases and 90% of chronic cases. The
rates of patients free from TMA events (no reduction in
platelets >25%; with no need for PT or new dialysis sessions)
were 88% and 80%, accompanied by a significant reduction
in the rate of daily interventions for TMA (PE or PI sessions
or new dialysis sessions) from baseline values of 6 and 1.5,
respectively, to 0 (P<.0001). At the end of the follow-up
period, GFR had increased significantly for both patient
groups (resistant patients: +31ml/min/1.73m2; P=.0001;
chronic patients: +6.1ml/min.1.73m2; P=.0003), and 80% of
resistant patients who were on dialysis at the start of
treatment (4 out of 5) were able to exit dialysis by the end of
the treatment period. We also observed that patients who
started treatment with eculizumab during the first 10 days
following the diagnosis of aHUS exhibited a greater increase
in GFR than those who started treatment after 2-4 months
(+59ml/min/1.73m2 vs. +7ml/min/1.73m2; P=.03). In
extended studies (62-64 weeks mean follow-up period), the
improvement in renal function was maintained.6-9 After one
year of eculizumab treatment, proteinuria levels were
significantly lower than baseline values (P=.05). Adverse side
effects were observed in 19 patients, including 4 severe
adverse effects (peritonitis, influenza infection, venous
disorder, and severe hypertension). Due to its mechanism of
action, eculizumab increases the risk of infection by
Neisseria meningitidis, which prompted to vaccination of all
patients against Neisseria (tetravalent vaccine) before starting
treatment or antibiotic prophylaxis, with no cases of
meningitis produced. Survival was 100% in both studies.
Another retrospective study involved 19 paediatric patients
treated in clinical practice with eculizumab for a mean 28
weeks.4,11 In this study, 89% of patients obtained normal
platelet levels and 68% were free of TMA events. The rate of
interventions for TMA was reduced from ~3/patient/week to
0. Mean GFR increased by ≥15ml/min/1.73m2 in 47% of
patients, and the need for dialysis was eliminated in 50% of
patients. The most common adverse effects of treatment
were pyrexia (47%), diarrhoea (32%), and upper respiratory
tract infections (32%).
Based on these results, the FDA (Food and Drug
Administration) and the EMA approved in the United States
and Europe, respectively, the indication for eculizumab in
the treatment of aHUS.4 The recent availability of this drug
in Spain has offered the possibility of substantially
improving the management of patients with aHUS, since the
approved indication authorises its use as a primary treatment.
Here, we present the recommendations for treating aHUS as
compiled by the authors of this document based on the
available evidence and pertinent clinical experience.
RECOMMENDATIONS FOR THE MANAGEMENT OF
ATYPICAL HAEMOLYTIC URAEMIC SYNDROME
Treatment recommendations
Considering the technical difficulties involved in
administering PT to paediatric patients (due to body size), as
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Table 6. Cases published of patients with atypical haemolytic uraemic syndrome who received eculizumab
PATIENTS WITH aHUS IN NATIVE KIDNEYS
Reference Mutation Response to Baseline serum Patient Last serum
plasma therapy creatinine, µmol/l evolution creatinine value, µmol/l
(66, 76) Not identified Resistant to 265 Remission after 3 years 35
plasma exchange
(77) CFH Partially responsive 80 Remission after 10 weeks 26
to plasma exchange
(78)a Not identified Resistant to plasma 690 Recurrence after 2 weeks Terminal renal failure
exchange
(79)a Not identified Resistant to plasma ~310 Recurrence after 2 weeks Terminal renal failure
exchange
(80) CFH S1191L Resistant to plasma 108 Remission after 15 months 44
V1197A infusion
(81) CFI p.A258T Resistant to plasma 610 Remission after 7 months 230
exchange
(31, 82)b Not identified No plasma therapy 600 Remission after 6 months 125
administered
(67) CFH C611Y Intolerance to plasma ~230 Remission after 24 months ~100
exchange
(99) Not identified Resistant to plasma ~325 (dialysis) Remission after 9 months ~80
exchange
(100) CFH Resistant to plasma ~310 (dialysis) Remission after 18 months ~75
exchange
(101) MCP c.286+ Resistant to plasma Dialysis Normalised haematological Terminal renal failure
1G>C exchange parameters. Irreversible renal 
damage impeded recovery  
of renal function
(102) Not identified Resistant to Continuous Remission 18
plasma infusion haemodiafiltration after one year
(84) CFH Resistant to plasma (dialysis) Remission >2.5 years 26.5
3355 G>a; exchange
Asp1119Asn; 
SCR19; SCR19
TRANSPLANTED RENAL PATIENTS
Preventative use of eculizumab
Reference Mutation Prior transplants Response to Baseline serum Patient evolution  Last serum 
(number) plasma therapy creatinine creatinine
measurement, µmol/L measurement,
µmol/l
(72) CFH W1183C No Responsive to ~45 No recurrence 44
plasma exchange
(73) CFH E1198stop No No plasma therapy Dialysis No recurrence Normal
administered
(74) CFH:CFHR1 No Responsive to plasma Dialysis No recurrence 80
hybrid gene exchange
(89) CFH:CFHR1 No Responsive to Dialysis No recurrence Normal
hybrid gene plasma exchange
Use of eculizumab to treat post-transplant recurrence of aHUS
(68)a CFH Y475S Yes (1) Resistant to plasma 132 Graft loss ne
exchange
(68)a CFH Y475S Yes (1) Resistant to plasma 132 Graft loss ne
exchange
(69, 83) C3 R570Q Yes (1) Responsive to plasma 320 2 recurrences in cases 230
exchange of delayed administration 
of eculizumab
Continues on next page >>
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well as the potential complications that arise from this strategy,
the early use of eculizumab in this population is especially
highly indicated, thus avoiding the need for PE. As such, given
a suspicion of aHUS in a paediatric patient, it is recommended
to provide early treatment with eculizumab as the first choice
(Figure 5). In adult patients with the suspicion of aHUS, early
eculizumab is also recommended. In the case that the start of this
treatment might be delayed, early and intensive PE should be
administered until eculizumab is an available option.62
Prior to this point, it is necessary to first vaccinate all
patients against Neisseria meningitidis (preferably with
conjugated tetravalent vaccines against serotypes A, C, Y,
and W135). In the case that treatment with eculizumab
cannot be delayed until obtaining proper vaccination,
treatment can still be started along with antibiotic
prophylaxis4 against Neisseria meningitidis based on the
protocol at each hospital. Considering the more elevated
rate of invasive infection by meningococci in paediatric
patients, as well as the absence of protection against
serotype B infections (which is the most prevalent type
due to the systematic vaccination of the other serotypes),
these patients should be maintained on antibiotic
prophylaxis with penicillin or amoxicillin to accompany
Figure 5. Treatment for atypical haemolytic uraemic syndrome.
PE: plasma exchange; aHUS: atypical haemolytic uraemic syndrome.
Continues table 6. Cases published of patients with atypical haemolytic uraemic syndrome who received eculizumab.
(70) Not specified No Resistant to plasma 323 Remission 238
exchange
(71) CFH S1191L Yes (2) Intolerance to plasma 131 Remission 130
exchange
(103)a Not identified No Resistant to plasma exchange 415 Graft loss na
(35) CFH Yes (1) Resistant to plasma exchange 500 Remission 62
(54) C3 R570W Yes (2) Partially responsive 220 Remission 115
to plasma exchange
(75) CFH E3514Stop No Partially responsive 565 (dialysis) Remission 229
to plasma exchange
(104) Not identified Yes (1) Resistant to plasma 449 (dialysis) Recurrence 5 months na
exchange after suspension of 
eculizumab. Graft loss
a Received one single dose of eculizumab. b Reduced levels of eculizumab.
CFH: complement factor H gene; CFHR1: complement factor H-related protein 1 gene; CFI: complement factor I gene; na: not
specified; HUS: haemolytic uraemic syndrome; aHUS: atypical haemolytic uraemic syndrome.
Clinical suspicion of aHUS
• Blood sample taken
for later analysis prior
to the start of
treatment
• Anti-meningococcus
vaccination ±
antibiotic prophylaxis
Treatment monitored
Paediatric patients:
early administration of eculizumab as the treatment of choice 
±
Support treatment
Adult patients:
early administration of eculizumab (early and intensive PE until
start of eculizumab therapy whenever a delay is warranted) 
±
Support treatment
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eculizumab.2 In adult patients, antibiotic prophylaxis
should be maintained throughout the duration of treatment
with eculizumab as based on the attending physician’s
judgement and patient characteristics. In paediatric
patients, vaccination against Haemophilus influenzae and
pneumococci is also necessary, along with strict adherence
to local guidelines regarding obligatory vaccinations for
each age group.
When patients exhibit a positive response to eculizumab,
treatment should be extended (chronic) as advised by the
drug technical data sheet.4 It is currently impossible to
provide recommendations regarding the most appropriate
duration of treatment, although as our experience with this
drug continues to develop, we may be able to evaluate the
possibility of treatment removal in certain low-risk patients
on an individual basis. In patients with clinical indications
requiring the removal of treatment, subsequent care must
include close monitoring for at least 12 weeks in order to
detect possible abnormalities suggestive of TMA.4 In these
cases, patients should be evaluated for reintroduction to
eculizumab and/or treatment with PE.4
When considering the application of PT in patients with aHUS,
PE with FFP should be preferentially evaluated (1.5 per volume
plasma [60-75ml/kg] per session). Sessions should continue until
platelet levels have normalised, haemolysis has stopped, and a
sustained improvement in renal function has been observed for
several days. Later, 5 sessions per week should be administered
during the following 2 weeks, followed by another two weeks of
3 sessions per week and an individualised assessment for
considering the appropriateness of continued treatment.2,62
Figure 6. Diagnosis and treatment of thrombotic microangiopathy in kidney transplants.
a Normally, deterioration in renal function with no haematological manifestations.
CMV: cytomegalovirus; CNI: calcineurin inhibitors; TCRF: terminal chronic renal failure; TMA: thrombotic microangiopathy; AHR:
acute humoral rejection; HUS: haemolytic uraemic syndrome; aHUS: atypical haemolytic uraemic syndrome.
Elevated clinical suspicion of post-transplant TMA 
(non-immune haemolytic anaemia + thrombocytopenia
+  graft dysfunction)
Individualised evaluation of the need for renal biopsy
History of 
aHUS-caused
TCRF
TMA with no
history of aHUS
Secondary 
TMA
Probable recurrence
(complete differential
diagnosis)
de novo aHUSa
AHR
CMV
BK virus
Evaluate early use of
eculizumab
Plasma
exchanges 
+ 
removal of CNI
Aetiological 
treatment
Evaluate eculizumab
in resistant cases
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Immunosuppression therapy should be administered as a
concomitant treatment in patients with aHUS and anti-FH
antibodies on PT.22,57,63,64 The response to treatment in these
cases should be monitored through the evolution of
antibody titres.57
Whenever necessary, support measures can be put into
place to control hypertension and volemia. For the
treatment of anaemia, red blood cell transfusions and/or
erythropoietin stimulating factors can be administered.
Platelet transfusions should be limited to cases of severe
platelet depletion (<30 000mm3) or in rare cases of
severe haemorrhage or in anticipation of invasive
procedures with a risk of major blood loss, since this
could worsen the TMA phenomena. Another priority is
the identification and treatment of possible triggering
agents of aHUS. Paediatric patients with aHUS should
be transferred to specialised paediatric nephrology
centres for treatment from experienced personnel with
the availability of a paediatric intensive care unit in
order to guarantee appropriate care.
Recommendations for transplantation in
patients with atypical haemolytic uraemic
syndrome
Prior evaluation
In patients with TCRF and aHUS who are candidates for KT,
an exhaustive analysis is first required to determine plasma
levels of C3, C4, FH, FI, and FB, as well as MCP expression
in peripheral leukocytes.35 A complete genetic analysis
should also be performed in order to detect known
complement mutations (and polymorphisms associated with
risk factors), along with a screening process for anti-FH
antibodies.35 Based on these analyses, the patient should be
evaluated on an individual basis for the indications for KT
and its concomitant treatment, based on the risk of
recurrence of aHUS.
Clinically, aHUS is considered as a contraindication for live
kidney donation (especially in patients with high-risk
mutations) due to the elevated rates of recurrence and graft
loss, as well as the risk that the donor could have undetected
complement mutations that would facilitate the development
of aHUS.1,53,87 Currently, the advancements in genetic
diagnostics and the use of eculizumab could allow for
considering these patients for live kidney donation through
an individualised evaluation of select cases. In the case of
related donors, a complete genetic-molecular analysis is also
required. As a general rule, the transplant should only be
considered as a viable option if the recipient mutations
known to be associated with aHUS have already been
identified, and these mutations have been ruled out in the
potential donor.
Treatment and prophylaxis for the recurrence of
atypical haemolytic uraemic syndrome following
transplantation
Treatment for recurrence of disease in patients who receive
kidney transplants for aHUS should be provided under the
same framework as for aHUS in native kidneys, based on
early administration of eculizumab,6-9,35,54,70,71,75,88 while taking
into account the usefulness and convenience of applying
PE. Figure 6 displays a management algorithm for the
primary causes of TMA in KT.
Before the availability of eculizumab, it was impossible to
recommend single kidney transplants in patients with TCRF
secondary to aHUS on dialysis with a high risk of recurrence
of disease following transplantation (patients with high-risk
mutations and/or episodes of recurrence of aHUS). In recent
years, several initial pilot studies have been reported with
positive experience with the use of eculizumab as
prophylaxis in paediatric patients with FH mutations prior to
KT from cadaveric donors,72-74,89 suggesting that KT along
with preventative treatment with eculizumab could be the
indicated treatment option for these patients. Recently, a
study administered prophylactic eculizumab to 9 patients in
order to prevent the recurrence of aHUS following KT.88 This
study involved 6 paediatric patients and 3 adults with
different mutations to the alternative complement pathway (5
FH mutations, 1 C3, and 3 patients with non-homologous
genomic reorganisations between CFH and CFHR1 genes).
Two patients received post-KT PE and were then transferred
to treatment with eculizumab, 2 received eculizumab starting
at the week prior to transplantation (live unrelated donor,
urgent transplant from cadaveric donor), and the remaining 5
received eculizumab immediately following transplantation.
Except for one case involving an early thrombosis that led to
graft loss, the other 8 cases had favourable evolution with no
recurrences after a mean follow-up period of 14.5 months
(mean creatinine: 71.6±44.8µmol). In this context, the recent
guidelines from an aHUS research group in France
recommended prophylaxis with eculizumab in patients with
TCRF secondary to aHUS who are candidates for KT.90
In children with aHUS that have mutations to genes that
code for complement factors synthesised in the liver (FH,
FB, or FI), liver/kidney and liver transplants have been
performed in order to correct the consequences of the
genetic defect and prevent disease recurrence. This
strategy, combined with perioperative administration of
plasma (in order to provide sufficient functional
complement factors until the liver graft recovers its ability
for synthesis) or eculizumab, has produced successful
results in several cases, yielding good liver function and no
aHUS recurrence to date.91-95 However, it is essential to
evaluate the risk and the morbidity/mortality associated
with these procedures, as well as the possible secondary
side effects from the long-term immunosuppression
special article
41
Josep M. Campistol et al. Update for atypical haemolytic uraemic síndrome
Nefrologia 2013;33(1):27-45
required by transplant recipients. It is also unclear whether
the minimal extra-hepatic synthesis of FH (in adipose
tissue, renal tissue, and monocytes) could induce
recurrence of aHUS in the post-transplant period.2
Taking into account that calcineurin inhibitors can be
associated with post-transplant TMA due to their
nephrotoxic effect, these drugs must be used with caution
in patients with aHUS who have received transplants. To
this end, a treatment regimen free of calcineurin
inhibitors based on belatacept and/or mTOR inhibitors
could be a possibility, taking into account the
immunological risk of the patient, although no conclusive
data are available regarding the most appropriate
immunosuppression regimen for the at-risk population.
CONCLUSIONS
• aHUS is caused by a deregulation of genetic origin of
the activation of the alternative complement system
pathway on cell surfaces, leading to the development
of systemic TMA. In recent years, several mutations
and polymorphisms have been identified in the genes
of certain complement factors that have been related
to this deregulation.
• This syndrome is characterised clinically by the triad
of non-immune microangiopathic haemolytic anaemia,
thrombocytopenia, and acute renal dysfunction, com-
monly associated with extra-renal manifestations. The
prognosis varies based on the type of mutation present,
although in general, the syndrome is associated with
high mortality rates and occurrence of TCRF, despite
standard treatment with PT. There is also an elevated
rate of recurrence of aHUS following KT. 
• Given clinical signs and symptoms suggestive of
TMA, the diagnosis must be orientated towards aHUS
if the shiga toxin/STEC test is negative, plasma acti-
vity of ADAMTS13 is >5%, and secondary forms of
HUS have been ruled out.
• Eculizumab is a monoclonal antibody that inhibits the
activation of C5 and the formation of the cell membra-
ne attack complex, which is responsible for the dama-
ge produced to native cell structures in aHUS. In pros-
pective studies involving patients with aHUS,
eculizumab effectively interrupted the process of
TMA, associated in the long-term with significant hae-
matological improvements and recovery of renal func-
tion.
• The FDA, the EMA, and the Spanish Agency of Me-
dicines have approved the use of eculizumab for the
treatment of aHUS, authorising its use as a first line of
treatment. The authors of this document recommend
its early use in patients with a clinical suspicion of
aHUS in native kidneys, as well as in patients with re-
current aHUS following KT.
Table 7. Protocol for sample collection for complement
analyses in patients with atypical haemolytic uraemic
syndrome.
In the case of samples to be sent to a reference laboratory, it is
strongly recommended to contact first with this laboratory and
strictly follow their instructions regarding what is required to
perform the complement studies.
If no reference laboratory is available and the patient's samples are
going to be stored for future analyses, the samples obtained
should include:
- 10ml of blood with EDTA
- 10ml of coagulated blood for serum.
- If the patient is a small child and 20ml of blood cannot be
extracted, 2-3ml can be obtained for each sample (6-9ml total).
- Blood with EDTA must be centrifuged immediately at 3000rpm
for 10 minutes at 4ºC, followed by plasma collection in a sterile
tube, taking care not to absorb any red blood cells. After
labelling five tubes with patient name, date, and a mark
indicating EDTA plasma, the plasma is distributed into these
tubes for immediate freezing, keeping samples stored at -80ºC. 
- After removing the EDTA-plasma, store the cellular pellet frozen
at -80ºC. This will be used to obtain DNA.
- Coagulated blood for one hour at room temperature is
centrifuged at 3000rpm for 10 minutes at 4ºC, immediately
separating the serum from the blood, taking care not to collect
any red blood cells in the sterile tube. After labelling five tubes
with patient name, date, and a mark indicating serum, the
serum is distributed into these tubes for immediate freezing,
keeping samples stored at -80ºC.
APPENDIX 1. RECOMMENDATIONS FOR THE
TREATMENT OF SECONDARY FORMS OF
HAEMOLYTIC URAEMIC SYNDROME
The management of secondary forms of HUS should be based
on the primary aetiology of the disease and the administration
of PE. In the case of resistance to treatment, eculizumab should
be administered (probably on a temporary basis) as a salvage
therapy in selected severe cases,96-98 although little data is avail-
able to establish a concrete recommendation in this context.
APPENDIX 2. RECOMMENDATIONS OF INTEREST
FOR THE DIAGNOSIS OF GENETIC ABNORMALITIES
Although not necessary for the clinical diagnosis of aHUS, a
complete evaluation of the complement system is recommend-
ed, including plasma levels of all complement factors and a
complete genetic analysis of affected patients. Samples should
be taken prior to the start of treatment and sent to a reference
laboratory (Table 7). Taking into account that complement mu-
tations have been identified for STEC-HUS and secondary
HUS, it is also recommended that these patients undergo an in-
dividualised genetic analysis in order to examine the possible
correlation with complement abnormalities/aHUS.2
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However, a genetic diagnosis of abnormal complement genes
would allow for assessing prognosis on an individual bases,
as well as the risk of recurrence of disease, making this a rec-
ommended step for all patients. In patients who are potential
candidates for KT, the genetic analysis is indispensable.
An online database of complement mutations in patients with
aHUS is currently available in Spain to facilitate data collec-
tion and future studies: https://www.tmaddd.es.
We also recommend taking graft samples from patients who
receive kidney transplants due to aHUS for future studies.
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